




PHARMACEUTICAL 2023

NeuBase Therapeutics Inc.
Rank 271 of 446





PHARMACEUTICAL 2023

NeuBase Therapeutics Inc.
Rank 271 of 446

The relative strengths and weaknesses of NeuBase Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NeuBase Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 32% points. The greatest weakness of NeuBase Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 29%, being 14% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	24,649
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,166
Liabilities, Non-Current	5,335
Other Assets	5,888
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-458
Other Revenues	0
Property and Equipment	2,157
Research and Development	21,449
Selling, General and Administrative Expense	11,870

Output Variable	Value in 1000 USD
Assets	32,693
Liabilities	9,502
Expenses	33,318
Revenues	0
Stockholders Equity	23,192
Net Income	-33,776
Comprehensive Net Income	-33,776
Economic Capital Ratio	29%